Refine Search
(0)
(0)
(0)
(5)

New Cancer Drugs

Developments within the oncology space have reached exciting levels of innovation in recent years, as cutting-edge immunological therapies continue to demonstrate impressive levels of efficacy in clinical trials. If cancer drugs currently being investigated are approved in the future, traditional drugs and chemotherapy treatments, which are replete with side effects and not always curative, could soon become a thing of the past.

EpiCast Report: Colorectal Cancer – Epidemiology Forecast to 2025

  • $3,995
  • December 2016
Add to Basket Quick View Add to Saved List

Colorectal cancer (CRC) is a cancer that starts in the colon or the rectum (ACS, 2016). CRC is one of the most common types of cancers diagnosed. For this analysis, GlobalData epidemiologists defined CRC as a cancer in all sub-sites of the colo...

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2025

  • $10,995
  • December 2016
Add to Basket Quick View Add to Saved List

Human epidermal growth factor receptor type 2 (HER2-) breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer can be subdivided into hormone receptor-positive (HER2-...

Pancreatic Cancer Global Clinical Trials Review, H1, 2017

  • $2,500
  • February 2017
Add to Basket Quick View Add to Saved List

GlobalData's clinical trial report, “Pancreatic Cancer Global Clinical Trials Review, H1, 2017" provides an overview of Pancreatic Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on P...

OpportunityAnalyzer: Bladder Cancer – Opportunity Analysis and Forecasts to 2025

  • $10,995
  • April 2017
Add to Basket Quick View Add to Saved List

The bladder cancer market in the seven major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, and Japan) has remained largely unchanged in the past 10-20 years. However, significant expansion is expected starting in 2016, with the...

OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025

  • $10,995
  • May 2017
Add to Basket Quick View Add to Saved List

Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-...